DSM-265

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H12F7N5S
Molecular Weight	415.332
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=NC(=NN2C(NC3=CC=C(C=C3)S(F)(F)(F)(F)F)=C1)C(C)(F)F

InChI

InChIKey=OIZSVTOIBNSVOS-UHFFFAOYSA-N

InChI=1S/C14H12F7N5S/c1-8-7-11(26-13(22-8)24-12(25-26)14(2,15)16)23-9-3-5-10(6-4-9)27(17,18,19,20)21/h3-7,23H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C14H12F7N5S
Molecular Weight	415.332
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28363637 | https://adisinsight.springer.com/drugs/800039314 | https://newdrugapprovals.org/2016/05/23/dsm-265-a-promising-antimalarial/

DSM265 is an experimental antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase (DHODH). DSM265 is the first DHODH inhibitor to reach clinical development for treatment of malaria. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drug-resistant parasite isolates. The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dihydroorotate dehydrogenase 9 Target ID: CHEMBL3486 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21696174	Inhibitor 8297

PubMed

Title	Date	PubMed
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.	2011 Aug 11	21696174
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.	2015 Jul 15	26180101
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.	2017 Jun	28363637
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.	2017 Jun	28363636
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria.	2018 Aug	29909070
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.	2018 Feb 14	29216395
DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum.	2019 Apr	30858218
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.	2019 Jan 11	30375858

Patents

Sample Use Guides

In Vivo Use Guide

Single dose of 400 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:44:49 GMT 2023` Edited by `admin` on `Sat Dec 16 11:44:49 GMT 2023`
Record UNII	0Q42P4YI6B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DSM-265

Common Name

English

2-(1,1-DIFLUOROETHYL)-5-METHYL-N-(4-(PENTAFLUORO-.LAMBDA.6-SULFANYL)PHENYL) (1,2,4)TRIAZOLO(1,5-A)PYRIMIDIN-7-AMINE

Systematic Name

English

SULFUR, (4-((2-(1,1-DIFLUOROETHYL)-5-METHYL(1,2,4)TRIAZOLO(1,5-A)PYRIMIDIN-7-YL)AMINO)PHENYL)PENTAFLUORO-, (OC-6-21)-

Systematic Name

English

DSM265

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

598417